Table 3. Clinical multivariate analysis for progression-free survival (C-model).

Variable	HR (CI 95%)	P value
Disease-free interval (≥24 vs < 24 months)	0.74 (0.35-1.59)	0.43
Estrogen-receptor (positive vs negative)	0.41 (0.17-1.03)	0.06
Prior anthracyclines and taxanes (yes vs no)	1.02 (0.52-2.01)	0.94
Prior lines for metastatic disease (≥ 1 vs 0)	1.55 (0.8-3)	0.19
Metastatic location (< 3 locations and no liver involvement vs ≥ 3 or hepatic)	3.07 (1.63-5.8)	0.0005